RNS60辅助治疗急性缺血性卒中的随机概念验证试验(RESCUE)
RESCUE是一项随机、双盲、安慰剂对照的2期试验,纳入82例接受血管内取栓的大血管闭塞急性缺血性卒中患者,按1:1:1分配接受48小时RNS60 0.5 mL/kg/h、1.0 mL/kg/h或安慰剂输注。主要终点严重不良事件率和死亡率在三组相似,RNS60 1.0 mL/kg/h组48小时梗死体积增长较安慰剂减少47%(21.4 mL vs 40.6 mL,P<0.05),其他疗效终点无统计学差异。结论认为RNS60安全耐受,1.0 mL/kg/h可减少取栓后梗死增长,需更大样本试验验证。
要点
- RNS60 1.0 mL/kg/h组48小时梗死体积增长较安慰剂减少47%(P<0.05)。
- 三组严重不良事件率与死亡率相似,RNS60安全耐受。
- 其他疗效终点无统计学差异,需更大样本试验验证。
核心结论
- RNS60安全且耐受良好,1.0 mL/kg/h可减少血管内取栓后的梗死体积增长,提示获益需更大规模试验验证。
研究设计与样本
- 随机、多中心、安慰剂对照、双盲2期试验,纳入82例大血管闭塞急性缺血性卒中患者。
- 按1:1:1分配至48小时输注RNS60 0.5 mL/kg/h、RNS60 1.0 mL/kg/h或安慰剂1.0 mL/kg/h,随访90天。
- 主要终点为严重不良事件率和死亡率。
主要发现
- 严重不良事件率在RNS60 0.5 mL/kg/h、1.0 mL/kg/h和安慰剂组分别为33.3%、25.0%和28.6%。
- 死亡率在RNS60 0.5 mL/kg/h、1.0 mL/kg/h和安慰剂组分别为6.7%、8.3%和14.3%。
- RNS60 1.0 mL/kg/h组48小时梗死体积增长较安慰剂减少47%(21.4 mL [IQR 5.0-29.1] vs 40.6 mL [IQR 6.3-62.3],P<0.05)。
- 其他疗效终点无统计学显著差异,但RNS60 1.0 mL/kg/h组第90天改良Rankin量表0-2分和Barthel指数≥95的比例更高。
关键数值与推荐
- RNS60 1.0 mL/kg/h组48小时梗死体积增长21.4 mL(IQR 5.0-29.1),安慰剂组40.6 mL(IQR 6.3-62.3),P<0.05。
- 严重不良事件率:RNS60 0.5 mL/kg/h组33.3%,1.0 mL/kg/h组25.0%,安慰剂组28.6%。
- 死亡率:RNS60 0.5 mL/kg/h组6.7%,1.0 mL/kg/h组8.3%,安慰剂组14.3%。
临床怎么用
- 对于接受血管内取栓的大血管闭塞急性缺血性卒中患者,辅助RNS60 1.0 mL/kg/h可能减少梗死体积增长,但当前证据尚不足以改变临床实践。
局限性
- 样本量小(82例),为概念验证试验,其他疗效终点无统计学显著差异,需更大规模试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite significant improvements in early reperfusion, many patients with acute ischemic stroke with large vessel occlusion experience poor outcomes, which indicates a clear need for adjunct therapies. RNS60 is a proprietary combination of oxygen supersaturated in saline with cerebroprotective and immunomodulatory effects. RNS60 showed therapeutic promise in rodent and nonhuman primate models of acute ischemic stroke. RESCUE (A Randomized, Blinded, Placebo-controlled, Parallel Group Design to Determine the Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy) was the proof-of-concept trial testing adjunctive treatment with RNS60 in patients with acute ischemic stroke with large vessel occlusion undergoing endovascular thrombectomy with or without prior treatment with an intravenous thrombolytic. METHODS: This randomized multicenter, placebo-controlled, double-blind, phase 2 study enrolled 82 participants, assigned 1:1:1 to 48-hour infusion of RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, or placebo 1.0 mL/kg per hour, and followed for 90 days. Rates of serious adverse events and mortality were the primary end points. Efficacy end points included the modified Rankin Scale score, infarct volume growth, National Institutes of Health Stroke Scale, worsening of stroke, Barthel Index, and the EuroQoL health-related quality of life scale. RESULTS: The RNS60 groups met the primary end points with similar rates of serious adverse events (33.3%, 25.0%, and 28.6%) and fewer deaths (6.7%, 8.3%, and 14.3%) across RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, and placebo, respectively. The RNS60 1.0 mL/kg per hour group showed reduced infarct growth by 47% at 48 hours post-endovascular thrombectomy (21.4 mL [interquartile range, 5.0-29.1] versus 40.6 mL [interquartile range, 6.3-62.3]; P<0.05). No statistically significant differences were observed in other efficacy end points, but a higher proportion of participants in the RNS60 1.0 mL/kg per hour group had reduced disability (modified Rankin Scale score of 0-2) and functional independence (Barthel Index ≥95) on Day 90. CONCLUSIONS: RNS60 was safe and well tolerated. The RNS60 1.0 mL/kg per hour reduced infarct growth after endovascular thrombectomy compared with placebo. This suggests a benefit warranting investigation in a larger, appropriately powered trial. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04693715.
引用
- Ghosh S, Dubow JS, Sutherland J, et al. Randomized, Proof-of-Concept Trial (RESCUE) of RNS60 as an Adjunct Therapy in Acute Ischemic Stroke. Stroke. 2025. PMID: 40671649. doi:10.1161/STROKEAHA.125.051179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。